Genotyping Neisseria gonorrhoeae gyrA and penA antimicrobial genes from remnant Neisseria gonorrhoeae positive Cepheid Xpert® clinical specimens - A feasibility study.

TitleGenotyping Neisseria gonorrhoeae gyrA and penA antimicrobial genes from remnant Neisseria gonorrhoeae positive Cepheid Xpert® clinical specimens - A feasibility study.
Publication TypePublication
Year of Publication2020
AuthorsQadir S, Ellis O, Keizur EM, Stafylis C, Cortado R, Klausner JD
Corporate AuthorsAdolescent Trials Network(ATN) CARES Team
JournalJ Microbiol Methods
Volume168
Pagination105783
Date Published2020 Jan
ISSN1872-8359
KeywordsDNA Gyrase, Drug Resistance, Bacterial, Feasibility Studies, Female, Genotype, Genotyping Techniques, Gonorrhea, Humans, Microbial Sensitivity Tests, Neisseria gonorrhoeae, Pharynx, Real-Time Polymerase Chain Reaction, Rectum, Serine-Type D-Ala-D-Ala Carboxypeptidase, Vagina
Abstract

<p>Neisseria gonorrhoeae (NG) has developed resistance to most antibiotics, making it increasingly difficult to treat. Previous studies have predicted antimicrobial NG susceptibility based on the antimicrobial gene target DNA gyrase subunit A (gyrA) codon serine 91 and the penicillin-binding protein 2 (penA) using Roche Cobas® and Hologic APTIMA™ clinical specimens. We studied whether similar methods could be used on remnant NG-positive Cepheid Xpert® specimens.</p>
DOI10.1016/j.mimet.2019.105783
Alternate JournalJ Microbiol Methods
PubMed ID31760050